173 related articles for article (PubMed ID: 24123778)
1. Surface modifications of influenza proteins upon virus inactivation by β-propiolactone.
She YM; Cheng K; Farnsworth A; Li X; Cyr TD
Proteomics; 2013 Dec; 13(23-24):3537-47. PubMed ID: 24123778
[TBL] [Abstract][Full Text] [Related]
2. Topological N-glycosylation and site-specific N-glycan sulfation of influenza proteins in the highly expressed H1N1 candidate vaccines.
She YM; Farnsworth A; Li X; Cyr TD
Sci Rep; 2017 Aug; 7(1):10232. PubMed ID: 28860626
[TBL] [Abstract][Full Text] [Related]
3. Reactions of beta-propiolactone with nucleobase analogues, nucleosides, and peptides: implications for the inactivation of viruses.
Uittenbogaard JP; Zomer B; Hoogerhout P; Metz B
J Biol Chem; 2011 Oct; 286(42):36198-214. PubMed ID: 21868382
[TBL] [Abstract][Full Text] [Related]
4. Treatment of influenza virus with beta-propiolactone alters viral membrane fusion.
Bonnafous P; Nicolaï MC; Taveau JC; Chevalier M; Barrière F; Medina J; Le Bihan O; Adam O; Ronzon F; Lambert O
Biochim Biophys Acta; 2014 Jan; 1838(1 Pt B):355-63. PubMed ID: 24140008
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous quantification of hemagglutinin and neuraminidase of influenza virus using isotope dilution mass spectrometry.
Williams TL; Pirkle JL; Barr JR
Vaccine; 2012 Mar; 30(14):2475-82. PubMed ID: 22197963
[TBL] [Abstract][Full Text] [Related]
6. Examination of the effects of virus inactivation methods on the induction of antibody- and cell-mediated immune responses against whole inactivated H9N2 avian influenza virus vaccines in chickens.
Astill J; Alkie T; Yitbarek A; Taha-Abdelaziz K; Bavananthasivam J; Nagy É; Petrik JJ; Sharif S
Vaccine; 2018 Jun; 36(27):3908-3916. PubMed ID: 29853199
[TBL] [Abstract][Full Text] [Related]
7. Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production.
Herrera-Rodriguez J; Signorazzi A; Holtrop M; de Vries-Idema J; Huckriede A
Vaccine; 2019 Mar; 37(12):1630-1637. PubMed ID: 30765167
[TBL] [Abstract][Full Text] [Related]
8. Beta-Propiolactone Inactivation of Coxsackievirus A16 Induces Structural Alteration and Surface Modification of Viral Capsids.
Fan C; Ye X; Ku Z; Kong L; Liu Q; Xu C; Cong Y; Huang Z
J Virol; 2017 Apr; 91(8):. PubMed ID: 28148783
[TBL] [Abstract][Full Text] [Related]
9. Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity.
Budimir N; Huckriede A; Meijerhof T; Boon L; Gostick E; Price DA; Wilschut J; de Haan A
PLoS One; 2012; 7(1):e30898. PubMed ID: 22303469
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the beta-propiolactone sensitivity and optimization of inactivation methods for human influenza H3N2 virus.
Sasaki Y; Yoshino N; Sato S; Muraki Y
J Virol Methods; 2016 Sep; 235():105-111. PubMed ID: 27142111
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of SARS-CoV-2 by β-propiolactone causes aggregation of viral particles and loss of antigenic potential.
Gupta D; Parthasarathy H; Sah V; Tandel D; Vedagiri D; Reddy S; Harshan KH
Virus Res; 2021 Nov; 305():198555. PubMed ID: 34487766
[TBL] [Abstract][Full Text] [Related]
12. N-Linked Glycan Sites on the Influenza A Virus Neuraminidase Head Domain Are Required for Efficient Viral Incorporation and Replication.
Östbye H; Gao J; Martinez MR; Wang H; de Gier JW; Daniels R
J Virol; 2020 Sep; 94(19):. PubMed ID: 32699088
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of different inactivation methods for high and low pathogenic avian influenza viruses in egg-fluids for antigen preparation.
Pawar SD; Murtadak VB; Kale SD; Shinde PV; Parkhi SS
J Virol Methods; 2015 Sep; 222():28-33. PubMed ID: 25997377
[TBL] [Abstract][Full Text] [Related]
14. β-Propiolactone (BPL)-inactivation of SARS-Co-V-2: In vitro validation with focus on saliva from COVID-19 patients for scent dog training.
Pilchová V; Prajeeth CK; Jendrny P; Twele F; Meller S; Pink I; Fathi A; Addo MM; Volk HA; Osterhaus A; von Köckritz-Blickwede M; Schulz C
J Virol Methods; 2023 Jul; 317():114733. PubMed ID: 37068591
[TBL] [Abstract][Full Text] [Related]
15. N-Glycosylation Fingerprinting of Viral Glycoproteins by xCGE-LIF.
Hennig R; Rapp E; Kottler R; Cajic S; Borowiak M; Reichl U
Methods Mol Biol; 2015; 1331():123-43. PubMed ID: 26169738
[TBL] [Abstract][Full Text] [Related]
16. Principles of selective inactivation of viral genome. VI. Inactivation of the infectivity of the influenza virus by the action of beta-propiolactone.
Budowsky EI; Friedman EA; Zheleznova NV; Noskov FS
Vaccine; 1991 Jun; 9(6):398-402. PubMed ID: 1887669
[TBL] [Abstract][Full Text] [Related]
17. Critical assessment of influenza VLP production in Sf9 and HEK293 expression systems.
Thompson CM; Petiot E; Mullick A; Aucoin MG; Henry O; Kamen AA
BMC Biotechnol; 2015 May; 15():31. PubMed ID: 25981500
[TBL] [Abstract][Full Text] [Related]
18. A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice.
Freyn AW; Ramos da Silva J; Rosado VC; Bliss CM; Pine M; Mui BL; Tam YK; Madden TD; de Souza Ferreira LC; Weissman D; Krammer F; Coughlan L; Palese P; Pardi N; Nachbagauer R
Mol Ther; 2020 Jul; 28(7):1569-1584. PubMed ID: 32359470
[TBL] [Abstract][Full Text] [Related]
19. Site-specific glycosylation profile of influenza A (H1N1) hemagglutinin through tandem mass spectrometry.
Cruz E; Cain J; Crossett B; Kayser V
Hum Vaccin Immunother; 2018 Mar; 14(3):508-517. PubMed ID: 29048990
[TBL] [Abstract][Full Text] [Related]
20. Development and fit-for-purpose verification of an LC-MS method for quantitation of hemagglutinin and neuraminidase proteins in influenza virus-like particle vaccine candidates.
Guo J; Lu Y; Zhang Y; Mugabe S; Wei Z; Borisov OV
Anal Biochem; 2020 Mar; 592():113577. PubMed ID: 31926146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
